Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia
复制标题
DOI：
10.1182/blood-2016-06-719294
复制
发表时间：
2017-03-16
期刊：
影响因子：
20.3
通讯作者：
Wiestner, Adrian
中科院分区：
文献类型：
--
作者：
Ahn, Inhye E.;Underbayev, Chingiz;Wiestner, Adrian
接受伊鲁替尼治疗的慢性淋巴细胞白血病（CLL）患者的疾病进展归因于BTK和PLCG2的组织学转化或获得性突变。PD的耐药率和克隆组成尚未完全确定。我们在一项研究者发起的2期试验中报告了单药伊鲁替尼治疗CLL患者。中位随访时间为34个月，84例可评估患者中有15例（17.9%）出现进展。研究开始时复发/难治性疾病、TP53畸变、晚期Rai期和高β -2微球蛋白与较低的无进展生存期独立相关(P
Disease progression in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib has been attributed to histologic transformation or acquired mutations in BTK and PLCG2. The rate of resistance and clonal composition of PD are incompletely characterized. We report on CLL patients treated with single-agent ibrutinib on an investigator-initiated phase 2 trial. With median follow-up of 34 months, 15 of 84 evaluable patients (17.9%) progressed. Relapsed/refractory disease at study entry, TP53 aberration, advanced Rai stage, and high beta-2 microglobulin were independently associated with inferior progression-free survival (P